Six Years And Four Trials Later, LABA/ICS Combos Twist Free Of Box Warning
Executive Summary
US FDA concludes that combination products do not increase risk of serious asthma-related events compared to inhaled corticosteroids alone.
You may also be interested in...
FDA Supersizes Its Order For LABA Safety Studies
The trials, which follow a label change and new REMS, will encompass seven times the patients included in the studies submitted to FDA for approval.
FDA Calls For Class-Wide REMS For LABA Asthma Drugs
On top of a class-wide Risk Evaluation and Mitigation Strategy for the long acting beta-2 adrenergic agonist class of asthma drugs, FDA is going to work through its Safe Use partners to monitor whether actual use adjusts based on the new safety measures
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.